Investor Presentaiton
R&D investor presentation
35
In the STEP 4 trial, people on semaglutide sustained weight loss
versus placebo and experienced a 18.2% weight loss after 68 weeks
STEP 4 showed significantly greater weight loss
post run-in than placebo
Randomisation
Data from STEP 4
% change in
body weight
0
-2
-4
-6
-8
-10
-12
-10.5%
-14
-16
-18
-20
0
4
8 12 16 20 24 28
36
Placebo: -5.2%
•
Semaglutide: -18.2%
44
52
60
68
Time since initiation (weeks)
Change in body weight in % depicts observed means since time of randomisation; trial product estimand.
BMI: body mass index
•
Average age 46
79% women
Average BMI
38.4 kg/m²
Trial highlights that obesity is a chronic
disease requiring sustained treatment
Improvements on a panel of
cardiovascular risk markers
novo nordiskView entire presentation